欧洲机构建议核准对严重COVID-19呼吸困难进行新的治疗。 European agency recommends approval for new treatment for severe COVID-19 respiratory distress.

欧洲药品机构委员会建议批准InflaRx的GOHIBIC(vilobelimab)在特殊情况下治疗患有严重SARS-COV-2引起的呼吸困难综合症的成年人。 The European Medicines Agency's committee has recommended approval for InflaRx's GOHIBIC (vilobelimab) to treat adults with severe SARS-CoV-2-induced respiratory distress syndrome under exceptional circumstances. 维洛贝利马布是为接受皮质类固醇治疗和机械呼吸的患者提供. Vilobelimab is intended for patients on corticosteroids and mechanical ventilation. 提出的积极建议是基于其改善患者结果和降低死亡率的潜力,预计将在大约两个月内获得最后批准。 The positive recommendation is based on its potential to improve patient outcomes and reduce mortality, and it is expected to receive final approval within about two months.